

United States Patent and Trademark Office



APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/764.050	01/19/2001	Tadashi Okamoto	35.C15261	6689
5514 7	7590 03/07/2003			
FITZPATRICK CELLA HARPER & SCINTO 30 ROCKEFELLER PLAZA NEW YORK, NY 10112			EXAMINER	
			TUNG, JOYCE	
			ART UNIT	PAPER NUMBER
			1637	1
			DATE MAILED: 03/07/2003	1>

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/764,050

Applicant(s)

Okamoto et al.

Examiner

Joyce Tung

Art Unit 1637

The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
Period f	or Reply		•	NONTHIO FROM		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the						
- If the p - If NO p - Failure - Any rep	date of this communication. seriod for reply specified above is less than thirty (30) days, a reply within the seriod for reply is specified above, the maximum statutory period will apply and to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of this patent term adjustment. See 37 CFR 1.704(b).	d will expire SIX (0 application to bec	ome ABAND	ONED (35 U.S.C. § 133).		
Status						
1) 💢	Responsive to communication(s) filed on Dec 30, 20	002		·		
2a) 🗌	This action is FINAL . 2b) This action is non-final.					
3) 🗆	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.					
Disposit	tion of Claims					
4) 💢	Claim(s) <u>1-26</u>			is/are pending in the application.		
4	la) Of the above, claim(s)			is/are withdrawn from consideration.		
5) 🗆	Claim(s)			is/are allowed.		
6) 💢	Claim(s) 1-26			is/are rejected.		
	Claim(s)			1		
8) 🗆	Claims					
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are a) accepted or b) objected to by the Examiner.						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11)	The proposed drawing correction filed on					
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some* c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No.						
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).						
*S	see the attached detailed Office action for a list of the					
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).						
a) The translation of the foreign language provisional application has been received.						
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachm		4) Interview	Summary (P3	O-413) Paper No(s)		
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)		5) Notice of Informal Patent Application (PTO-152)				
	offermation Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:				

Application/Control Number: 09/764,050 Page 2

Art Unit: 1637

Response to Amendment

- 1. The amendment filed 12/30/2002 has been entered.
- 2. The rejection of claims 1-26 under 35 U.S.C. §112, second paragraph, is withdrawn.
- 3. The rejection of claims 1-7, 9, 11-14, 18, 20-21 and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sutherland et al. (WO 87/06956), in view of Johann et al. (6,277,628) and Kang et al. (6,268,131) is withdrawn.
- 4. The rejection of claim 10 under 35 U.S.C. 103(a) as being unpatentable over Sutherland et al. (WO 87/06956), in view of Johann et al. (6,277,628) and Kang et al. (6,268,131) as applied to claims 1-7, 9, 11-14, 18, 20-21 and 25 above, and further in view of Miyakoshi et al. (JP404330300) is withdrawn.
- 5. The rejection of claims 15, 17, 19, 22-24 and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sutherland et al. (WO 87/06956), in view of Johann et al. (6,277,628) and Kang et al. (6,268,131) as applied to claims 1-7, 9, 11-14, 18, 20-21 and 25 above, and further in view of Yamamoto et al. (Nucleic Acid Research, 1995, Vol. 23(8), pg. 1445-1446).

New Grounds of Rejections

Claim Rejections - 35 USC § 112

6. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Application/Control Number: 09/764,050 Page 3

Art Unit: 1637

7. Claim 8 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the

invention.

a. Claim 8 is vague and indefinite because it is unclear why the solvent including said

hybrid (C) and said fluorescence dye (D) having acted on said hybrid is removed by gas flow

between steps (1) and (2). It appears that drying said hybrid (C) and said fluorescence dye (D) on

said substrate is for the detection/quantification of target nucleotide chains. It is possible that

applying gas flow is for drying said hybrid (C) and said fluorescence dye (D) on said substrate.

Clarification is required.

Claim Rejections - 35 USC § 103

8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later

Application/Control Number: 09/764,050

Art Unit: 1637

invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

9. Claims 1-7, 9, 11-14, 18, 20-21 and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sutherland et al. (WO 87/06956) in view of Johann et al. (6,277,628). Sutherland et al. disclose a waveguide coated with single-stranded probe nucleic acid in which the single-stranded sample nucleic acid is allowed to react with the probe in the presence of intercalant fluorescence dyes (See pg. 5, fifth paragraph). An analyte solution contains test DNA or RNA (See the Abstract). A double stranded DNA is used with ethidium bromide (See pg. 36, third paragraph). The waveguide substance is a plastic cuvette (See pg. 40, claim 14).

Sutherland et al. do not disclose drying the hybrid and the fluorescence dye on the substrate.

Johann et al. disclose a method and a composition for detecting the levels of a plurality of biomolecular probes in a sample. In particular the invention relates to a hybridization composition for detecting the presence or the levels of different polynucleotide sequences in a sample (See the Abstract). The biomolecular probe comprises polynucleotide probes and the target are complementary polynucleotide sequences (See column 1, lines 55-57) in which target is immobilized (See column 1, lines 45-48). The target can be DNA or RNA (See column 5, lines 20-36). The labels can be fluorescent markers and dyes (See column 5, lines 37-48). The labeling moiety can be incorporated after hybridization once a probe-target complex is formed (See column 5, lines 49-53). The Cy5-5' labeled 59mer was used to fill a glass bead capillary

Application/Control Number: 09/764,050

Art Unit: 1637

array, washed and then dried. The array was detected by a confocal fluorescence microscope (See column 8, lines 22-32).

One of ordinary skill in the art at the time of the instant invention would have been motivated to apply the drying step of Johann et al. (See column 8, lines 22-32) to the method of Sutherland et al. because with the drying step, the method of Johann et al. is high throughput hybridization experiments utilizing small sample as desired (See column 2, lines 32-35). Thus, it would have been prima facie obvious to apply Johann et al. dry step to Sutherland et al. 's detection assay in order to carry out the claimed method.

Claim 10 is rejected under 35 U.S.C. 103(a) as being unpatentable over Sutherland et al. 8. (WO 87/06956), in view of Johann et al. (6,277,628) as applied to claims 1-7, 9, 11-14, 18, 20-21 and 25 above, and further in view of Miyakoshi et al. (JP404330300).

The teachings of Sutherland et al., and Johann et al. are set forth in section 7 above and Sutherland et al. and Johann et al. do not discloses using resin as solid- phase substrate as claimed in claim 10.

Miyakoshi et al. disclose that a resin membrane is used to efficiently immobilize a shortchain nucleic acid, thus simplifies operation of hybridization (See the Abstract).

Thus, one of ordinary kill in the art at the time of the instant invention would have been motivated to apply resin membrane as solid phase substrate because a resin membrane was used to efficiently immobilize a short-chain nucleic acid, thus simplifies operation of hybridization

Art Unit: 1637

(See the Abstract). It would have been <u>prima facies</u> obvious to apply resin membrane as solid phase substrate as claimed.

9. Claims 15, 17, 19, 22-24 and 26 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sutherland et al. (WO 87/06956), in view of Johann et al. (6,277,628) as applied to claims 1-7, 9, 11-14, 18, 20-21 and 25 above, and further in view of Yamamoto et al. (Nucleic Acid Research, 1995, Vol. 23(8), pg. 1445-1446).

The teachings of Sutherland et al. and Johann et al. are set forth in section 7 above and Sutherland et al. and Johann et al. do not discloses using pyrylium salt and YOYO-1 as intercalator as claimed in claims 15,17, 19, 22-24 and 26.

Yamamoto et al. disclose a new method of detecting the nucleic acid amplified products using a fluorescent intercalator pyrylium salt (P2) which shows strong fluorescence when reacted with double stranded DNA(dsDNA) in proportion to the amount of dsDNA (See pg. 1445, third paragraph). YOYO-1 has also a large increase of fluorescence intensity when it is intercalated into dsDNA (See pg. 1446, second paragraph).

Thus, one of ordinary kill in the art at the time of the instant invention would have been motivated to apply the fluorescence intercalator of Yamamoto et al. to the method of Sutherland et al. because of the benefit of using the fluorescent intercalator pyrylium salt (P2) and YOYO-1 as discussed above. It would have been <u>prima facie</u> to use a fluorescent intercalator pyrylium salt (P2) and YOYO-1.

Application/Control Number: 09/764,050 Page 7

Art Unit: 1637

Summary

12. No claims are allowable.

13. Any inquiries concerning this communication or earlier communications from the examiner should be directed to Joyce Tung whose telephone number is (703) 305-7112. The examiner can normally be reached on Monday-Friday from 8:00 AM-4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at (703) 308-1119 on Monday-Friday from 10:00 AM-6:00 PM.

Any inquiries of a general nature or relating to the status of this application should be directed to the Chemical/Matrix receptionist whose telephone number is (703) 308-0196.

14. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Art Unit 1637 via the PTO Fax Center located in Crystal Mall 1 using (703) 305-3014 or 308-4242. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989).

Joyce Tung

February 28, 2003

Jeffrey Siew Primary Examiner 3/6/03